Optimal therapeutic range for oral anticoagulants.

[1]  Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis , 1978 .

[2]  L. Poller,et al.  An Evaluation of Chromogenic Substrates in the Control of Oral Anticoagulant Therapy , 1981, British journal of haematology.

[3]  Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. , 1982 .

[4]  A. Turpie.  Anticoagulant therapy after acute myocardial infarction. , 1990, The American journal of cardiology.

[5]  C. Francis,et al.  Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. , 1983, JAMA.

[6]  M Gent,et al.  Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. , 1979, The New England journal of medicine.

[7]  J. Hirsh,et al.  RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENT , 1988, The Lancet.

[8]  J. Hirsh.  Is the dose of warfarin prescribed by American physicians unnecessarily high? , 1987, Archives of internal medicine.

[9]  L. Poller,et al.  Dosage and control of oral anticoagulants: an international collaborative survey , 1982, British journal of haematology.

[10]  S. Zucker,et al.  Standardization of laboratory tests for controlling anticoagulent therapy. , 1970, American journal of clinical pathology.

[11]  G. Gogstad,et al.  Utility of a Modified Calibration Model for Reliable Conversion of Thromboplastin Times to International Normalized Ratios , 1986, Thrombosis and Haemostasis.

[12]  I. Wright,et al.  Myocardial infarction and its treatment with anticoagulants; summary of findings in 1031 cases. , 1954, Lancet.

[13]  Gershwin Me,et al.  Letter: Loss of suppressor function as a cause of lymphoid malignancy. , 1974 .

[14]  L. Poller,et al.  Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. , 1987, British medical journal.

[15]  T B Kirkwood,et al.  Calibration of Reference Thromboplastins and Standardisation of the Prothrombin Time Ratio , 1983, Thrombosis and Haemostasis.

[16]  A Drapkin,et al.  Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. , 1972, JAMA.

[17]  G. Blackburn,et al.  Prophylaxis against central vein thrombosis with low-dose warfarin. , 1986, Surgery.

[18]  O. Orning,et al.  The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. , 1969, The American journal of cardiology.

[19]  W. Morse,et al.  THROMBOPLASTIC FACTORS IN THE ESTIMATION OF PROTHROMBIN CONCENTRATION , 1948, The American journal of the medical sciences.

[20]  E. Loeliger.  ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. , 1985, Haematologica.

[21]  D A Taberner,et al.  Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR) , 1989, Journal of clinical pathology.

[22]  T. Hilden,et al.  ANTICOAGULANTS IN ACUTE MYOCARDIAL INFARCTION , 1961 .

[23]  I. Wright.  Recent developments in antithrombotic therapy. , 1969, Annals of internal medicine.

[24]  D. Tweedle.  INTRAVENOUS FAT , 1976, The Lancet.

[25]  M. Verstraete,et al.  Use of Different Tissue Thromboplastins in the Control of Anticoagulant Therapy , 1957, Circulation.

[26]  G. Raskob,et al.  Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. , 1982, The New England journal of medicine.

[27]  E. Loeliger.  Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation. , 1985, Acta haematologica.